Skip to main navigation Skip to search Skip to main content

Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

  • Jessica R. Bauman
  • , Geoffrey Liu
  • , Isabel Preeshagul
  • , Stephen V. Liu
  • , Barbara Melosky
  • , Devin Abrahami
  • , Benjamin Li
  • , Despina Thomaidou
  • , Kirsten Duncan
  • , Stan Krulewicz
  • , Martin Rupp
  • , Jessica J. Lin
  • Princess Margaret Cancer Centre
  • Memorial Sloan-Kettering Cancer Center
  • Georgetown University
  • British Columbia Cancer Agency
  • Pfizer
  • Massachusetts General Hospital Cancer Center

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry